article thumbnail

FDA orders Sun to hire manufacturing consultant for troubled plant as export pause persists

Fierce Pharma

FDA orders Sun to hire manufacturing consultant for troubled plant as export pause persists fkansteiner Tue, 05/16/2023 - 09:33

article thumbnail

B2B Sales Consulting for Medical Sales: A Comprehensive Guide

Rep-Lite

B2B sales consulting for medical sales is a specialized service that helps healthcare organizations navigate the unique challenges of B2B transactions within the healthcare industry. What is B2B Sales Consulting? B2B sales consulting involves working with businesses to enhance their sales strategies and operations in a B2B context.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA approves first Stelara biosimilar, Wezlana

European Pharmaceutical Review

The US Food and Drug Administration ( FDA) has approved Wezlana (ustekinumab-auub) as a biosimilar to Johnson & Johnson’s Stelara (ustekinumab). The evidence also demonstrated that Wezlana met the other legal requirements to be interchangeable with Stelara at the pharmacy level, without consulting the prescriber.

article thumbnail

Body Vision Medical Accelerates International Expansion with Business Asia Consultants, Inc., Partnership

Legacy MEDSearch

Body Vision Medical, a leader in AI-driven, intraoperative imaging, announced a new partnership with Business Asia Consultants (BAC), Inc. Body Vision Medical’s LungVision system was FDA cleared in 2019 and received CE Mark in 2021. About Business Asia Consultants. Business Asia Consultants (BAC), Inc. Partnership.

article thumbnail

FDA Fast Track designation for photodynamic cancer therapy

European Pharmaceutical Review

Fast Track designation (FTD) has been granted for REM-001 therapy to treat unresectable cutaneous metastatic breast cancer (CMBC) by the US Food and Drug Administration (FDA). The post FDA Fast Track designation for photodynamic cancer therapy appeared first on European Pharmaceutical Review.

article thumbnail

As FDA inspections return, upholding compliance and maintaining GMP readiness is more crucial than ever

pharmaphorum

Now FDA on-site inspections have resumed, with regulatory authorities returning to physical sites. Throughout the pandemic, the lack of FDA inspections has created new challenges and heightened existing problems, largely due to delays in upgrading legacy facilities. Upgrading facilities. Ensuring GMP readiness.

FDA 82
article thumbnail

The Definition of Patient Safety and Implementing Technologies (PDA/FDA Joint Regulatory Conference 2023)

PharmaTech

Maik Jornitz, Principal Consultant, BioProcess Resources LLC, discusses the definition of patient safety and how to implement new technologies into upgraded facilities.

Safety 98